CY1116968T1 - Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια - Google Patents
Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσιαInfo
- Publication number
- CY1116968T1 CY1116968T1 CY20151101069T CY151101069T CY1116968T1 CY 1116968 T1 CY1116968 T1 CY 1116968T1 CY 20151101069 T CY20151101069 T CY 20151101069T CY 151101069 T CY151101069 T CY 151101069T CY 1116968 T1 CY1116968 T1 CY 1116968T1
- Authority
- CY
- Cyprus
- Prior art keywords
- painylamin
- active substance
- packaging containing
- nrc
- preparation
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000013543 active substance Substances 0.000 title 1
- 238000004806 packaging method and process Methods 0.000 title 1
- LCPGCGAJBOWMIP-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCPGCGAJBOWMIP-UHFFFAOYSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
- 238000004945 emulsification Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940100688 oral solution Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Ένα φαρμακευτικό σκεύασμα για λήψη από του στόματος το οποίο περιέχει μια αποτελεσματική ποσότητα NRC-AN-019 συμπεριλαμβανομένων των φαρμακευτικά αποδεκτών αλάτων και πολυμόρφων του, όπως Μορφή I, Μορφή II και Μορφή III, για τη βελτίωση της βιοδιαθεσιμότητας και προορίζεται για αυτο-γαλακτωματοποίηση κατά την επαφή του με το γαστρεντερικό υγρό. Η εφεύρεση σχετίζεται επίσης με μια διαδικασία για την παρασκευή στοματικού διαλύματος που περιέχει το NRC-AN-019 σε αποτελεσματική συγκέντρωση για την καλύτερη θεραπεία της Χρόνιας Μυελογενούς Λευχαιμίας ως αναστολέας της τυροσινικής κινάσης BCR-ABL και για τη θεραπεία άλλων όγκων, όπως καρκίνος της κεφαλής και του λαιμού, καρκίνος του προστάτη και τα συναφή.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1103860.1A GB2488788B (en) | 2011-03-07 | 2011-03-07 | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
EP11764851.9A EP2683381B1 (en) | 2011-03-07 | 2011-08-10 | Formulation comprising phenylaminopyrimidine derivative as active agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116968T1 true CY1116968T1 (el) | 2017-04-05 |
Family
ID=43923331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151101069T CY1116968T1 (el) | 2011-03-07 | 2015-11-26 | Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια |
Country Status (32)
Country | Link |
---|---|
US (1) | US9895367B2 (el) |
EP (1) | EP2683381B1 (el) |
JP (1) | JP5788534B2 (el) |
KR (1) | KR101767296B1 (el) |
CN (1) | CN103561742B (el) |
AP (1) | AP4076A (el) |
AU (1) | AU2011361921B2 (el) |
BR (1) | BR112013022930A2 (el) |
CA (1) | CA2829015C (el) |
CO (1) | CO6811851A2 (el) |
CY (1) | CY1116968T1 (el) |
DK (1) | DK2683381T3 (el) |
EA (1) | EA024610B1 (el) |
ES (1) | ES2554927T3 (el) |
GB (1) | GB2488788B (el) |
GE (1) | GEP20156410B (el) |
HR (1) | HRP20151382T1 (el) |
HU (1) | HUE025562T2 (el) |
IL (1) | IL228218A (el) |
MA (1) | MA35088B1 (el) |
MX (1) | MX339130B (el) |
MY (1) | MY158693A (el) |
NZ (1) | NZ614903A (el) |
PL (1) | PL2683381T3 (el) |
PT (1) | PT2683381E (el) |
RS (1) | RS54420B1 (el) |
SG (1) | SG193349A1 (el) |
SI (1) | SI2683381T1 (el) |
SM (1) | SMT201500235B (el) |
UA (1) | UA111074C2 (el) |
WO (1) | WO2012120328A1 (el) |
ZA (1) | ZA201306643B (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20211590T1 (hr) | 2015-12-18 | 2022-01-07 | Natco Pharma Ltd | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina |
EP3397242B1 (en) * | 2015-12-29 | 2021-02-03 | Noivita S.R.L.S. | Lipophilic formulations |
CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
CN107564610A (zh) * | 2017-10-20 | 2018-01-09 | 浙江中大元通特种电缆有限公司 | 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆 |
LT3765024T (lt) * | 2018-03-14 | 2024-02-26 | KaNDy Therapeutics Limited | Nauja farmacinė vaisto forma, apimanti dvigubo nk-1/nk-3 receptoriaus antagonistus |
EP3914234A4 (en) * | 2019-01-25 | 2022-09-14 | Shenzhen Pharmacin Co., Ltd. | PHARMACEUTICAL COMPOSITIONS |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
AU728698B2 (en) * | 1997-07-29 | 2001-01-18 | Boehringer Ingelheim International Gmbh | Self-emulsifying formulation for lipophilic compounds |
US6248354B1 (en) * | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
US7232825B2 (en) * | 2003-05-02 | 2007-06-19 | Guoqing P Chen | Phenylaminopyrimidine derivatives and methods of use |
EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
JP5184887B2 (ja) | 2004-09-09 | 2013-04-17 | ナトコ ファーマ リミテッド | bcr−ablキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体 |
US20080207904A1 (en) * | 2006-10-26 | 2008-08-28 | Macdonald Peter | Imatinib base, and imatinib mesylate and processes for preparation thereof |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
ES2357354T3 (es) * | 2007-04-30 | 2011-04-25 | Intezyne Technologies Inc. | Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos. |
US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
MX2010009401A (es) | 2008-03-04 | 2010-09-24 | Natco Pharma Ltd | Forma cristalina de derivado de fenilamino pirimidina. |
AU2009325091A1 (en) * | 2008-05-23 | 2010-06-17 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein inhibitor |
-
2011
- 2011-03-07 GB GB1103860.1A patent/GB2488788B/en not_active Expired - Fee Related
- 2011-08-10 HU HUE11764851A patent/HUE025562T2/en unknown
- 2011-08-10 SG SG2013067319A patent/SG193349A1/en unknown
- 2011-08-10 NZ NZ614903A patent/NZ614903A/en not_active IP Right Cessation
- 2011-08-10 JP JP2013557180A patent/JP5788534B2/ja not_active Expired - Fee Related
- 2011-08-10 BR BR112013022930A patent/BR112013022930A2/pt not_active IP Right Cessation
- 2011-08-10 EP EP11764851.9A patent/EP2683381B1/en active Active
- 2011-08-10 PL PL11764851T patent/PL2683381T3/pl unknown
- 2011-08-10 WO PCT/IB2011/001842 patent/WO2012120328A1/en active Application Filing
- 2011-08-10 KR KR1020137026440A patent/KR101767296B1/ko active IP Right Grant
- 2011-08-10 CA CA2829015A patent/CA2829015C/en not_active Expired - Fee Related
- 2011-08-10 MX MX2013010160A patent/MX339130B/es active IP Right Grant
- 2011-08-10 DK DK11764851.9T patent/DK2683381T3/en active
- 2011-08-10 CN CN201180069095.7A patent/CN103561742B/zh not_active Expired - Fee Related
- 2011-08-10 SI SI201130592T patent/SI2683381T1/sl unknown
- 2011-08-10 AP AP2013007128A patent/AP4076A/en active
- 2011-08-10 GE GEAP201113254A patent/GEP20156410B/en unknown
- 2011-08-10 MY MYPI2013003265A patent/MY158693A/en unknown
- 2011-08-10 US US14/003,445 patent/US9895367B2/en not_active Expired - Fee Related
- 2011-08-10 RS RS20150787A patent/RS54420B1/en unknown
- 2011-08-10 ES ES11764851.9T patent/ES2554927T3/es active Active
- 2011-08-10 EA EA201391280A patent/EA024610B1/ru not_active IP Right Cessation
- 2011-08-10 PT PT117648519T patent/PT2683381E/pt unknown
- 2011-08-10 AU AU2011361921A patent/AU2011361921B2/en not_active Ceased
- 2011-10-08 UA UAA201310715A patent/UA111074C2/uk unknown
-
2013
- 2013-09-01 IL IL228218A patent/IL228218A/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06643A patent/ZA201306643B/en unknown
- 2013-09-09 MA MA36236A patent/MA35088B1/fr unknown
- 2013-10-04 CO CO13236457A patent/CO6811851A2/es unknown
-
2015
- 2015-09-29 SM SM201500235T patent/SMT201500235B/xx unknown
- 2015-11-26 CY CY20151101069T patent/CY1116968T1/el unknown
- 2015-12-16 HR HRP20151382TT patent/HRP20151382T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116968T1 (el) | Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
CY1119090T1 (el) | Δευτεριωμενα παραγωγα ιβακαφτορης | |
CY1121416T1 (el) | Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων | |
CY1125613T1 (el) | 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
CY1118610T1 (el) | Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου | |
CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
MX2009013835A (es) | Forma de dosis estabilizada de picoplatino. | |
CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
CY1121089T1 (el) | Χρηση των παραγωγων της βενζιμιδαζολης-προλινης | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
EA201591024A1 (ru) | Димерные соединения | |
CY1124580T1 (el) | Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης | |
CL2014000441A1 (es) | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. |